Skip to main content


Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

Fig. 6

Overall clonogenic survival after fractionated multimodal treatment. a Molecular features (p53 mutation status, MGMT promotor methylation and gene expression) and determined plating efficiencies of glioblastoma cell lines and primary cells. NT means not tested. Data are means ± SEM from 3 independent experiments. b Overall surviving fractions of established cell lines after fractionated (7x), multimodal treatment with 0.25 μM SAR, 50 μM TMZ, 0.1 μM 5-aza-dC, and 2.2 Gy IR (total dose 15.4 Gy). Data are means ± SEM from 3 independent experiments (if not otherwise noted at the bottom of the bar) in sextuplicates. Significance of single treatments compared to untreated, non-irradiated control is indicated by asterisks (**, p ≤ 0.01; ***, p ≤ 0.001). Statistical significance of combined treatments with single drug plus IR compared to IR control is indicated by hashtags (##, p ≤ 0.01; ###, p ≤ 0.001). Selected significances of comparitive analyses are shown. c Time schedule of the fractionated multimodal treatment

Back to article page